138 related articles for article (PubMed ID: 28949774)
21. SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer.
Lui NS; Yang YW; van Zante A; Buchanan P; Jablons DM; Lemjabbar-Alaoui H
PLoS One; 2016; 11(2):e0148911. PubMed ID: 26882224
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study.
Trovo M; Giaj-Levra N; Furlan C; Bortolin MT; Muraro E; Polesel J; Minatel E; Tedeschi R; Filippi AR; Alongi F; Ricardi U
Clin Transl Oncol; 2016 Oct; 18(10):1003-10. PubMed ID: 26687367
[TBL] [Abstract][Full Text] [Related]
23. Lung cancer serum biomarker discovery using label-free liquid chromatography-tandem mass spectrometry.
Zeng X; Hood BL; Zhao T; Conrads TP; Sun M; Gopalakrishnan V; Grover H; Day RS; Weissfeld JL; Wilson DO; Siegfried JM; Bigbee WL
J Thorac Oncol; 2011 Apr; 6(4):725-34. PubMed ID: 21304412
[TBL] [Abstract][Full Text] [Related]
24. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
[TBL] [Abstract][Full Text] [Related]
25. Serum Protein Markers for the Early Detection of Lung Cancer: A Focus on Autoantibodies.
Broodman I; Lindemans J; van Sten J; Bischoff R; Luider T
J Proteome Res; 2017 Jan; 16(1):3-13. PubMed ID: 27769114
[TBL] [Abstract][Full Text] [Related]
26. [The assessment of acute phase proteins as prognostic factors in patients surgically treated for non-small cell lung cancer].
Kasprzyk M; Dyszkiewicz W; Zwaruń D; Leśniewska K; Wiktorowicz K
Pneumonol Alergol Pol; 2008; 76(5):321-6. PubMed ID: 19003761
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
[TBL] [Abstract][Full Text] [Related]
28. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?
Liu L; Liu N; Liu B; Yang Y; Zhang Q; Zhang W; Yu P; Jin Y; Guo J; Guan S; Sun S; Miao L; Wei J
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1737-42. PubMed ID: 22699933
[TBL] [Abstract][Full Text] [Related]
29. Optimal predictive value of preoperative serum carcinoembryonic antigen for surgical outcomes in stage I non-small cell lung cancer: differences according to histology and smoking status.
Kato T; Ishikawa K; Aragaki M; Sato M; Okamoto K; Ishibashi T; Oba K; Kaji M
J Surg Oncol; 2013 May; 107(6):619-24. PubMed ID: 23192365
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers and IL-2R in lung cancer.
Marino P; Preatoni A; Fonticoli L; Parodi M; Tarolo GL
Recenti Prog Med; 1990 Nov; 81(11):702-4. PubMed ID: 1962891
[TBL] [Abstract][Full Text] [Related]
31. Elevated serum apolipoprotein E is associated with metastasis and poor prognosis of non-small cell lung cancer.
Luo J; Song J; Feng P; Wang Y; Long W; Liu M; Li L
Tumour Biol; 2016 Aug; 37(8):10715-21. PubMed ID: 26873483
[TBL] [Abstract][Full Text] [Related]
32. Elevated lactic acid is a negative prognostic factor in metastatic lung cancer.
Vlachostergios PJ; Oikonomou KG; Gibilaro E; Apergis G
Cancer Biomark; 2015; 15(6):725-34. PubMed ID: 26406401
[TBL] [Abstract][Full Text] [Related]
33. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1.
Türeci O; Mack U; Luxemburger U; Heinen H; Krummenauer F; Sester M; Sester U; Sybrecht GW; Sahin U
Cancer Lett; 2006 May; 236(1):64-71. PubMed ID: 15992994
[TBL] [Abstract][Full Text] [Related]
34. Elastase levels in small and non-small cell lung carcinoma.
Güner G; Kirkali G; Baskin Y; Karlikaya C; Akkoçlu A
Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):305S. PubMed ID: 8224451
[No Abstract] [Full Text] [Related]
35. Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer.
Xu XY; Lin N; Li YM; Zhi C; Shen H
Pathol Res Pract; 2013 Jun; 209(6):345-52. PubMed ID: 23602236
[TBL] [Abstract][Full Text] [Related]
36. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
37. Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry.
Zeng X; Hood BL; Sun M; Conrads TP; Day RS; Weissfeld JL; Siegfried JM; Bigbee WL
J Proteome Res; 2010 Dec; 9(12):6440-9. PubMed ID: 20931982
[TBL] [Abstract][Full Text] [Related]
38. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
[TBL] [Abstract][Full Text] [Related]
39. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
Molina R; Augé JM; Bosch X; Escudero JM; Viñolas N; Marrades R; Ramírez J; Carcereny E; Filella X
Tumour Biol; 2009; 30(3):121-9. PubMed ID: 19506400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
